Clofert 25 mg (Clomiphene)

Product Overview

Clofert 25 mg is a prescription medication formulated to address ovulatory insufficiency in women seeking to conceive. Each tablet delivers 25 mg of clomiphene citrate, a selective estrogen receptor modulator that stimulates the hypothalamic‑pituitary axis to increase endogenous gonadotropin secretion. Svizera Maneesh Pharma manufactures the product in strips of ten film‑coated tablets, each designed for oral administration. The medication is packaged in strengths of 60, 90, or 120 tablets, providing flexible options for patients undergoing assisted reproductive therapy. Clofert is indicated for female infertility associated with polycystic ovary syndrome, primary ovarian insufficiency, or other functional ovulatory disorders. The product complies with international pharmacopeial standards and is subject to rigorous quality control by the manufacturer. For detailed regulatory information, refer to the MedlinePlus database.

What is Clofert 25 mg

Clofert 25 mg contains clomiphene citrate, a nonsteroidal selective estrogen receptor modulator (SERM) that acts primarily as an estrogen antagonist in the hypothalamus. By blocking estrogen receptors, clomiphene triggers a compensatory increase in the release of gonadotropin‑releasing hormone (GnRH), which in turn stimulates the anterior pituitary to secrete higher amounts of follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). This hormonal surge promotes the development of multiple ovarian follicles, enhancing the probability of ovulation in women who do not ovulate regularly. The drug is classified under fertility agents and is widely used in the field of reproductive endocrinology. Its pharmacological profile has been documented in peer‑reviewed literature, including studies indexed in PubMed, which confirm its role in inducing ovulation when administered during the early follicular phase of the menstrual cycle.

Uses and Benefits

Clofert 25 mg is primarily prescribed for women experiencing anovulation or oligo‑ovulation, conditions that contribute to infertility. Clinical guidelines recommend its use in patients with polycystic ovary syndrome (PCOS), hypothalamic amenorrhea, or unexplained ovulatory dysfunction. When taken as directed, the medication can increase the likelihood of ovulation by up to 80 % in this population, translating into higher conception rates when combined with timed intercourse or assisted‑reproductive procedures such as intrauterine insemination. In addition to its primary ovulatory‑inducing effect, Clofert may help regulate menstrual cycles, reduce androgen excess in PCOS, and improve endocrine profiles over successive treatment cycles. The therapeutic benefits are generally observed after three to six months of consistent use, provided that patients are monitored regularly. Evidence from systematic reviews, including those available on the National Institutes of Health website, supports the inclusion of clomiphene as a first‑line agent in infertility management.

How It Works

The mechanism of action of Clofert 25 mg centers on its selective modulation of estrogen receptors in the central nervous system. In the hypothalamus, clomiphene antagonizes estrogen receptors, leading to a perceived drop in circulating estrogen levels. This perception prompts the pituitary gland to increase the synthesis and release of FSH and LH. Elevated FSH stimulates the growth of multiple ovarian follicles, while the LH surge facilitates the final maturation and release of a dominant oocyte. The drug’s partial agonist activity in peripheral tissues minimizes estrogenic effects on the breast and endometrium, thereby reducing the risk of unwanted estrogenic side effects. Pharmacokinetic studies indicate that clomiphene reaches peak plasma concentrations within a few days of oral administration, with a half‑life that supports once‑daily dosing during the designated treatment window. Detailed pharmacokinetic data can be accessed through the U.S. Food and Drug Administration drug database.

Dosage Guidelines

Clofert 25 mg is typically administered orally for five consecutive days, beginning on the third to fifth day of the menstrual cycle, unless a different schedule is specifically prescribed by a qualified healthcare professional. The standard starting dose for most patients is one tablet daily; however, some clinicians may adjust the dose to two tablets per day based on prior response and tolerance. Treatment cycles are generally limited to a maximum of six ovulatory attempts to mitigate the risk of ovarian hyperstimulation syndrome. Patients should be instructed to swallow the tablet whole with water and to avoid crushing or chewing the film‑coated formulation. If a dose is missed, the patient should not double up on the next dose but should resume the regular schedule. Ongoing monitoring with transvaginal ultrasound and serum hormone assays is recommended to assess follicular development and to determine the optimal timing for intercourse or procedural intervention. Prescribing information emphasizes the importance of individualized dosing and close medical supervision.

Side Effects

Like all pharmacologic agents, Clofert 25 mg can be associated with adverse effects, although many are mild and transient. Commonly reported side effects include hot flashes, abdominal discomfort, breast tenderness, and occasional visual disturbances such as blurred vision or floaters. Less frequent but clinically significant events may involve ovarian hyperstimulation syndrome, characterized by abdominal distension, pelvic pain, and rapid weight gain, which require prompt medical evaluation. Mood changes, including irritability or mild depression, have also been documented in post‑marketing surveillance. Rarely, thromboembolic events or hepatic dysfunction may occur, particularly in patients with pre‑existing risk factors. Patients are advised to report any new or worsening symptoms to their physician immediately. For a comprehensive list of side effects, consult the prescribing information or reputable drug information resources such as Drugs.com.

Warnings and Precautions

Clofert 25 mg is contraindicated in individuals with known hypersensitivity to clomiphene or any excipients in the formulation, as well as in patients with ovarian cysts unrelated to polycystic ovary syndrome, uncontrolled thyroid or adrenal disorders, and hepatic disease. The medication should not be used during pregnancy or lactation, as it may interfere with fetal development and infant health. Prior to initiation, a thorough medical history should be obtained to identify risk factors for thromboembolic disease, such as smoking, obesity, or a personal history of blood clots. Concomitant use of hormonal therapies, including estrogen or progesterone supplements, may alter the expected response and should be reviewed with a healthcare provider. Patients should be counseled to avoid excessive alcohol consumption and to maintain a healthy body weight, as these factors can influence ovulation rates. Finally, regular follow‑up visits are essential to monitor ovarian response, adjust dosing if needed, and discontinue treatment if adverse reactions become clinically significant.

Frequently Asked Questions

Q: What is Clofert 25 mg used for? A: Clofert 25 mg is indicated for the treatment of female infertility caused by ovulatory dysfunction, including polycystic ovary syndrome and other hormonal disorders that prevent regular ovulation.

Q: How should I take Clofert 25 mg? A: The usual regimen is one tablet daily for five consecutive days, starting on the third to fifth day of the menstrual cycle, under the supervision of a qualified healthcare professional.

Q: When should I start taking Clofert? A: Treatment should begin on day 3‑5 of the menstrual cycle, after a baseline evaluation of hormone levels and ovarian ultrasound, to maximize the chance of follicular development.

Q: Are there any common side effects? A: Typical side effects include hot flashes, abdominal discomfort, breast tenderness, and occasional visual disturbances; however, serious events such as ovarian hyperstimulation require immediate medical attention.

Q: Can Clofert be used for male infertility? A: Clofert is formulated for female patients; its use in men is not approved and should only be considered under specialist guidance for specific hormonal disorders.

Related Products

• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 50 mg (Generic)
• Clomiphene 100 mg (Generic)
• Clomiphene 25 mg (Generic)
• Progesterone Vaginal Gel 1.125 g (Generic)
• Fertomid 25 mg (Clomiphene)
• Clofert 50 mg (Clomiphene)
• Clofert (Clomiphene)
• Clofert 100 mg (Clomiphene)